All In Biotech

Drug Trial Radar · NCT00650624

A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)

A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg QD Versus Placebo In Patients With OA Of The Knee

Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Jun 2003

Primary completion

Not stated

Study completion Jan 2004

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 2, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the therapeutic dose range of valdecoxib by comparing the efficacy of three dosing regimens (5 mg, 10 mg and 20 mg once daily) with placebo for relief of the signs and symptoms of osteoarthritis of the knee. To assess safety and tolerability of multiple doses of valdecoxib in patients with osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

  • valdecoxibDrug

    valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks

  • valdecoxibDrug

    valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks

  • valdecoxibDrug

    valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks

  • placeboDrug

    placebo tablet by mouth once daily in the morning for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. WOMAC (Western Ontario and McMaster Universities) OA Pain IndexTime frame: screening (Day -14), baseline (week 0), and at weeks 2, 4, and 6 (final visit)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Saga, Japan

  • Pfizer Investigational Site

    Tokyo, Japan

  • Pfizer Investigational Site

    Funabashi, Chiba, Japan

  • Pfizer Investigational Site

    Sakura, Chiba, Japan

  • Pfizer Investigational Site

    Chikushi-gun, Fukuoka, Japan

  • Pfizer Investigational Site

    Iizuka, Fukuoka, Japan

  • Pfizer Investigational Site

    Kurume, Fukuoka, Japan

  • Pfizer Investigational Site

    Yame, Fukuoka, Japan

  • Pfizer Investigational Site

    Chitose, Hokkaido, Japan

  • Pfizer Investigational Site

    Sapporo, Hokkaido, Japan

  • Pfizer Investigational Site

    Kamakura, Kanagawa, Japan

  • Pfizer Investigational Site

    Yokohama, Kanagawa, Japan

  • Pfizer Investigational Site

    Isahaya, Nagasaki, Japan

  • Pfizer Investigational Site

    Hirakata, Osaka, Japan

  • Pfizer Investigational Site

    Kanzaki-gun, Saga-ken, Japan

  • Pfizer Investigational Site

    Karatsu, Saga-ken, Japan

  • Pfizer Investigational Site

    Ogi-gun, Saga-ken, Japan

  • Pfizer Investigational Site

    Setagaya-ku, Tokyo, Japan

  • Pfizer Investigational Site

    Shinjuku-Ku, Tokyo, Japan

  • Pfizer Investigational Site

    tabashi City, Tokyo, Japan

  • Pfizer Investigational Site

    Taito-ku, Tokyo, Japan

  • Pfizer Investigational Site

    Yoyogi Shibuya-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.